PROK has 36-month beta value of 1.42. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for PROK is 75.82M, and currently, short sellers hold a 13.64% ratio of that float. The average trading volume of PROK on November 15, 2024 was 669.75K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PROK) stock’s latest price update
ProKidney Corp (NASDAQ: PROK)’s stock price has dropped by -16.51 in relation to previous closing price of 2.15. Nevertheless, the company has seen a loss of -10.25% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that WINSTON-SALEM, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2024, and gave several regulatory and clinical development updates.
PROK’s Market Performance
ProKidney Corp (PROK) has experienced a -10.25% fall in stock performance for the past week, with a -9.34% drop in the past month, and a -25.21% drop in the past quarter. The volatility ratio for the week is 9.75%, and the volatility levels for the past 30 days are at 7.87% for PROK. The simple moving average for the last 20 days is -1.35% for PROK’s stock, with a simple moving average of -16.97% for the last 200 days.
Analysts’ Opinion of PROK
Guggenheim, on the other hand, stated in their research note that they expect to see PROK reach a price target of $6. The rating they have provided for PROK stocks is “Buy” according to the report published on September 10th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to PROK, setting the target price at $3 in the report published on March 07th of the current year.
PROK Trading at -7.65% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.57% of loss for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 9.75%, as shares sank -7.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.10% lower at present.
During the last 5 trading sessions, PROK fell by -9.25%, which changed the moving average for the period of 200-days by +40.70% in comparison to the 20-day moving average, which settled at $1.82. In addition, ProKidney Corp saw 0.84% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Weber Darin J., who sale 16,412 shares at the price of $2.50 back on Sep 19 ’24. After this action, Weber Darin J. now owns 103,480 shares of ProKidney Corp, valued at $41,030 using the latest closing price.
DARIN J WEBER, the Officer of ProKidney Corp, proposed sale 16,412 shares at $2.39 during a trade that took place back on Sep 19 ’24, which means that DARIN J WEBER is holding shares at $39,225 based on the most recent closing price.
Stock Fundamentals for PROK
Current profitability levels for the company are sitting at:
- -23.89 for the present operating margin
- 0.37 for the gross margin
The net margin for ProKidney Corp stands at -11.31. The total capital return value is set at -0.24.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -23.75. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -17890.33.
Currently, EBITDA for the company is -147.67 million with net debt to EBITDA at 1.14. When we switch over and look at the enterprise to sales, we see a ratio of 96.07. The receivables turnover for the company is 0.88for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.09.
Conclusion
To put it simply, ProKidney Corp (PROK) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
